Percheron Therapeutics Ltd Annual Report and Appendix 4E
Key points
- Percheron Therapeutics Ltd has reported a significant loss for the year ended 30 June 2026.
- The company has successfully completed a phase I clinical trial for its drug HMBD-002.
- Percheron has licensed HMBD-002 and is preparing for a phase II clinical trial.
- Dr. Michael Baker has been appointed as the new CEO.
Full summary
Percheron Therapeutics Ltd (ASX: PER) has released its annual report for the year ended 30 June 2026, detailing a loss of $4,791,745, down 68% from the previous year. The loss includes full expensing of R&D costs and non-cash expenses. The company reported no dividends and a net tangible asset per share of 0.63 cents. Percheron has successfully completed a phase I clinical trial for its drug HMBD-002, a VISTA inhibitor, which showed excellent safety and potential efficacy. The company is preparing for a phase II clinical trial planned for the second half of CY2026. Percheron has licensed HMBD-002 and is exploring opportunities for potential grant funding. Dr. James Garner will step down as CEO, and Dr. Michael Baker has been appointed as his successor.
Guidance
Percheron Therapeutics Ltd reported a loss of $4,791,745 for the year ended 30 June 2026.
Outlook
Percheron Therapeutics Ltd plans to commence a phase II clinical trial for HMBD-002 in the second half of CY2026.
Summary generated by a large language model. Please interpret with care.